| Sep 27 |
Bluebird: Q2 Earnings Snapshot
|
| Sep 27 |
bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing
|
| Sep 26 |
bluebird bio: Scientific Success And Financial Success, And The Gap Between
|
| Sep 24 |
Gene Therapy-Focused Bluebird Bio Restructures, Cuts Is Workforce By 25%, Seeks To Breakeven Next Year
|
| Sep 24 |
bluebird bio to cut workforce by about 25%
|
| Sep 24 |
bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025
|
| Sep 13 |
bluebird bio completes restated 10-K, delays 2024 Q2 10-Q
|
| Sep 13 |
bluebird bio Announces Completion of its Restatement and filing of its 2023 Form 10-K and Q1 2024 Form 10-Q
|
| Aug 28 |
FDA will not meet ahead of bluebird bio’s sickle cell disease gene therapy PDUFA date
|
| Aug 28 |
bluebird bio Announces September Investor Events
|
